Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBITDA (2022 - 2025)

Gossamer Bio's EBITDA history spans 4 years, with the latest figure at -$47.3 million for Q4 2025.

  • For Q4 2025, EBITDA fell 59.68% year-over-year to -$47.3 million; the TTM value through Dec 2025 reached -$176.7 million, down 221.35%, while the annual FY2025 figure was -$176.7 million, 221.35% down from the prior year.
  • EBITDA reached -$47.3 million in Q4 2025 per GOSS's latest filing, up from -$48.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $49.3 million in Q2 2024 to a low of -$59.4 million in Q3 2022.
  • Average EBITDA over 4 years is -$40.1 million, with a median of -$44.9 million recorded in 2023.
  • Peak YoY movement for EBITDA: skyrocketed 215.99% in 2024, then tumbled 186.21% in 2025.
  • A 4-year view of EBITDA shows it stood at -$55.8 million in 2022, then grew by 14.12% to -$47.9 million in 2023, then soared by 38.16% to -$29.6 million in 2024, then tumbled by 59.68% to -$47.3 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's EBITDA are -$47.3 million (Q4 2025), -$48.2 million (Q3 2025), and -$42.5 million (Q2 2025).